Literature DB >> 20614336

Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer.

Jose E Barrera1, Kenneth R Shroyer, Sherif Said, George Hoernig, Raymond Melrose, Paul D Freedman, Tanya A Wright, Robert O Greer.   

Abstract

OBJECTIVES: The current study examined the role of estrogen receptors (ER), progesterone receptors (PR) and p53 expression in adenoid cystic carcinoma (ACC) to determine if simple expression or possible overexpression of these products might influence the development and natural course of this cancer. STUDY
DESIGN: ER and PR status and p53 overexpression were retrospectively evaluated utilizing immunohistochemical evaluation of 47 ACC specimens.
METHODS: Formalin-fixed paraffin-embedded tissues from 47 ACC specimens and 47 samples of normal salivary gland tissue were evaluated histochemically for the presence of ER, PR and p53. Immunoreactivity was scored using a 0 to +3 scale in which staining was either (0) negative, (+1) spotty, (+2) weakly positive, or (+3) strongly positive.
RESULTS: ER was expressed in 8 of 47 tumors while PR was expressed in 4 of 47 tumors. p53 aberrations were demonstrated in 26 of 47 tumors. Tumors showed varying degrees of immunopositivity ranging from 0 to +3.
CONCLUSIONS: These studies suggest that p53 aberrations may be involved in ACC tumor progression and that ER and PR may play a role in ACC development.

Entities:  

Keywords:  Adenoid cystic carcinoma; Estrogen and progesterone receptors; p53 gene

Mesh:

Substances:

Year:  2007        PMID: 20614336      PMCID: PMC2807605          DOI: 10.1007/s12105-007-0032-3

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  15 in total

1.  Progestational therapy in human renal carcinoma and steroid receptors.

Authors:  G Concolino; A Marocchi; F Di Silverio; C Conti
Journal:  J Steroid Biochem       Date:  1976 Nov-Dec       Impact factor: 4.292

Review 2.  Adenoid cystic carcinoma of the breast.

Authors:  J Y Ro; E G Silva; H S Gallager
Journal:  Hum Pathol       Date:  1987-12       Impact factor: 3.466

3.  The unique association between salivary gland cancer and breast cancer.

Authors:  J W Berg; R V Hutter; F W Foote
Journal:  JAMA       Date:  1968-05-27       Impact factor: 56.272

4.  Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences.

Authors:  A M Ruder; F Lubin; Y Wax; A Geier; E Alfundary; A Chetrit
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

5.  Adenoid cystic carcinoma of Bartholin's gland: review of the literature and report of two cases.

Authors:  F S Abrao; A F Marques; F Marziona; M S Abrao; L C Uchoa Junqueira; H Torloni
Journal:  J Surg Oncol       Date:  1985-10       Impact factor: 3.454

6.  Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands.

Authors:  T Kiyoshima; K Shima; I Kobayashi; K Matsuo; K Okamura; S Komatsu; A M Rasul; H Sakai
Journal:  Oral Oncol       Date:  2001-04       Impact factor: 5.337

7.  Estrogen receptors in normal salivary gland and salivary gland carcinoma.

Authors:  I W Dimery; L A Jones; R P Verjan; A K Raymond; H Goepfert; W K Hong
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-10

8.  The clinical value of multiple steroid receptor assays in breast cancer management.

Authors:  L G Skinner; D M Barnes; G G Ribeiro
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

9.  Immunohistochemical localization of estradiol, progesterone, and progesterone receptor in human salivary glands and salivary adenoid cystic carcinomas.

Authors:  S Ozono; M Onozuka; K Sato; Y Ito
Journal:  Cell Struct Funct       Date:  1992-06       Impact factor: 2.212

10.  Steroid hormone receptors in human colon cancers.

Authors:  T C Alford; H M Do; G W Geelhoed; N T Tsangaris; M E Lippman
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

View more
  7 in total

1.  Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.

Authors:  Nhu Thuy Can; Mark W Lingen; Heather Mashek; James McElherne; Renee Briese; Carrie Fitzpatrick; Annemieke van Zante; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2017-07-05

2.  Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: a single institutional experience at a tertiary care center.

Authors:  Anna Marcinow; Enver Ozer; Theodoros Teknos; Lai Wei; Agnes Hurtuk; Matthew Old; Amit Agrawal; Ricardo Carrau; Obiajulu H Iwenofu
Journal:  Head Neck       Date:  2014-02-01       Impact factor: 3.147

3.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

Review 4.  Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis.

Authors:  Qinglin Li; Ping Huang; Chuanming Zheng; Jiafeng Wang; Minghua Ge
Journal:  Oncotarget       Date:  2017-04-25

5.  Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma.

Authors:  Ana Amélia de Souza; Albina Altemani; Ney Soares de Araujo; Lucas Novaes Texeira; Vera Cavalcanti de Araújo; Andresa Borges Soares
Journal:  Clin Pathol       Date:  2019-09-26

6.  Multicentre clinicopathological study of adenoid cystic carcinoma: A report of 296 cases.

Authors:  Zheng Huang; Juan Pan; Jiaorong Chen; Shidi Wu; Ting Wu; Haihua Ye; Hongfeng Zhang; Xiu Nie; Changzheng Huang
Journal:  Cancer Med       Date:  2021-01-15       Impact factor: 4.452

7.  Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands.

Authors:  Matthijs H Valstar; Michael Schaapveld; Esther C van den Broek; Marie-Louise F van Velthuysen; Mischa de Ridder; Marjanka K Schmidt; Boukje A C van Dijk; Alfons J M Balm; Ludi E Smeele
Journal:  Cancer Med       Date:  2020-11-28       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.